Vanda Pharmaceuticals (VNDA) Enterprise Value (2010 - 2026)
Vanda Pharmaceuticals (VNDA) reported Enterprise Value of -$202.3 million for Q1 2026, up 40.66% on a YoY basis from -$143.8 million in Q1 2025, and up 23.32% sequentially from -$263.8 million in Q4 2025.
Vanda Pharmaceuticals (VNDA) Enterprise Value (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals (VNDA) has 17 years of Enterprise Value data on file, last reported at -$202.3 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value rose 40.66% year-over-year to -$202.3 million; the trailing twelve-month figure through Mar 2026 stood at -$202.3 million (up 40.66% YoY), and the FY2025 full-year result was -$263.8 million, up 29.57% from the prior year.
- Enterprise Value advanced to -$202.3 million in Q1 2026, from -$263.8 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$202.3 million in Q1 2026 to a low of -$501.5 million in Q1 2023.
- A 5-year average of -$389.7 million and a median of -$388.3 million in 2023 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value declined 15.24% in 2023 and jumped 40.66% in 2026, its largest moves.
- Tracing VNDA's Enterprise Value over 5 years: stood at -$466.9 million in 2022, then advanced by 16.83% to -$388.3 million in 2023, then climbed by 3.51% to -$374.6 million in 2024, then advanced by 29.57% to -$263.8 million in 2025, then climbed by 23.32% to -$202.3 million in 2026.
- Business Quant data shows VNDA's Enterprise Value at -$202.3 million in Q1 2026, -$263.8 million in Q4 2025, and -$293.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Vanda Pharmaceuticals | 318.71 Mn | 116.40 Mn | 48.56 Mn | -202.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -202.31 Mn |
| Dec 31, 2025 | -263.85 Mn |
| Sep 30, 2025 | -293.75 Mn |
| Jun 30, 2025 | -325.55 Mn |
| Mar 31, 2025 | -340.91 Mn |
| Dec 31, 2024 | -374.64 Mn |
| Sep 30, 2024 | -376.26 Mn |
| Jun 30, 2024 | -387.68 Mn |
| Mar 31, 2024 | -394.14 Mn |
| Dec 31, 2023 | -388.26 Mn |
| Sep 30, 2023 | -489.86 Mn |
| Jun 30, 2023 | -489.35 Mn |
| Mar 31, 2023 | -501.50 Mn |
| Dec 31, 2022 | -466.86 Mn |
| Sep 30, 2022 | -454.79 Mn |
| Jun 30, 2022 | -440.86 Mn |
| Mar 31, 2022 | -435.18 Mn |
| Dec 31, 2021 | -432.81 Mn |
| Sep 30, 2021 | -405.97 Mn |
| Jun 30, 2021 | -396.49 Mn |